Autopsy report · NCT04537806

A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)

“Internal company decision”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 6 months before it stopped.
• 29 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Sage Therapeutics

Sponsor type

Industry

Conditions

Acute Respiratory Distress Syndrome; COVID-19

Interventions

Brexanolone; Placebo

Participants

29

Sites

9

Countries

United States

Trials that died the same way

• Clinical Performance Evaluation of the Hativ P30
  “Company's internal decision.” (92% match in meaning)
• A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
  “Internal company decision (non-safety related)” (82% match in meaning)
• Influence of Variable Inflow Volume, Dwell Duration and Glucose Concentration on Ultrafiltration Volume in APD Patients
  “Internal decision” (81% match in meaning)
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants
  “internal company decision; not safety related” (79% match in meaning)
• Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC
  “Company Decision” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.